Fukutin: The FKTN gene (formerly known as FCMD) provides instructions for making a protein called fukutin.
1. Normal Function
This protein is present in many of the body's tissues but is particularly abundant in heart (cardiac) muscle, the brain, and the muscles used for movement (skeletal muscles). Within cells, fukutin is found in a specialized structure called the Golgi apparatus, where newly produced proteins are modified.
The fukutin protein is involved in a protein modification process called glycosylation. Through this chemical process, sugar molecules are added to certain proteins. In particular, the fukutin protein adds a molecule called ribitol 5-phosphate to the chain of sugars attached to a protein called alpha (α)-dystroglycan. Glycosylation is critical for the normal function of α-dystroglycan.
The α-dystroglycan protein helps anchor the structural framework inside each cell (cytoskeleton) to the lattice of proteins and other molecules outside the cell (extracellular matrix). In skeletal muscles, glycosylated α-dystroglycan helps stabilize and protect muscle fibers. In the brain, it helps direct the movement (migration) of nerve cells (neurons) during early development.
2. Health Conditions Related to Genetic Changes
2.1 Fukuyama Congenital Muscular Dystrophy
At least 18 mutations in the FKTN gene have been found to cause Fukuyama congenital muscular dystrophy, a condition that causes skeletal muscle weakness and brain and eye abnormalities. This form of congenital muscular dystrophy is seen almost exclusively in Japan. Virtually everyone with this condition has at least one copy of the same mutation, an insertion of about 3,000 extra DNA building blocks (3 kilobases [kb]) in the FKTN gene. This insertion occurs in a part of the gene known as the 3' untranslated region, which helps regulate the gene's activity. Researchers believe that the 3-kb insertion reduces the amount of fukutin protein that is produced from the gene.
A shortage of fukutin prevents the normal glycosylation of α-dystroglycan. As a result, α-dystroglycan can no longer effectively anchor cells to the proteins and other molecules that surround them. Without functional α-dystroglycan to stabilize the muscle fibers, they become damaged as they repeatedly contract and relax with use. The damaged fibers weaken and die over time, which affects the development, structure, and function of skeletal muscles in people with Fukuyama congenital muscular dystrophy.
Defective α-dystroglycan also affects the migration of neurons during the early development of the brain. Instead of stopping when they reach their intended destinations, some neurons migrate past the surface of the brain into the fluid-filled space that surrounds it. Researchers believe that this problem with neuronal migration causes a brain abnormality called cobblestone lissencephaly, in which the surface of the brain lacks the normal folds and grooves and instead appears bumpy and irregular. Less is known about the effects of FKTN mutations in other parts of the body.
2.2 Limb-Girdle Muscular Dystrophy
2.3 Walker-Warburg Syndrome
At least 11 FKTN gene mutations have been identified in people with Walker-Warburg syndrome, the most severe form of congenital muscular dystrophy. This condition is found in populations worldwide. Like Fukuyama congenital muscular dystrophy (described above), Walker-Warburg syndrome is associated with skeletal muscle weakness and eye and brain abnormalities, including cobblestone lissencephaly; however, individuals with Walker-Warburg syndrome have more severe brain and eye abnormalities and live only into infancy or early childhood. The FKTN gene mutations associated with this condition prevent the production of any functional fukutin protein, which leads to the severe muscle, eye, and brain problems that develop in Walker-Warburg syndrome.
2.4 Other Disorders
Mutations in the FKTN gene cause other disorders that affect skeletal muscles and the heart. Unlike Fukuyama congenital muscular dystrophy (described above), which is mostly limited to the Japanese population, these conditions have been described in several populations worldwide.
Several people with a heart condition called dilated cardiomyopathy have been found to have mutations in the FKTN gene. This condition weakens and enlarges the heart, preventing it from pumping blood efficiently. When dilated cardiomyopathy is associated with FKTN gene mutations, it is known as type 1X (DCM1X). In addition to heart problems, some people with DCM1X have experienced mild skeletal muscle weakness beginning in adulthood.
Changes in the FKTN gene that reduce but do not eliminate the production of fukutin lead to the somewhat less severe medical problems seen in DCM1X and limb-girdle muscular dystrophy (linked above).
3. Other Names for This Gene
Fukuyama type congenital muscular dystrophy protein
The entry is from https://medlineplus.gov/genetics/gene/fktn
- Cotarelo RP, Valero MC, Prados B, Peña A, Rodríguez L, Fano O, Marco JJ,Martínez-Frías ML, Cruces J. Two new patients bearing mutations in the fukutingene confirm the relevance of this gene in Walker-Warburg syndrome. Clin Genet.2008 Feb;73(2):139-45. doi: 10.1111/j.1399-0004.2007.00936.x.
- de Bernabé DB, van Bokhoven H, van Beusekom E, Van den Akker W, Kant S, DobynsWB, Cormand B, Currier S, Hamel B, Talim B, Topaloglu H, Brunner HG. A homozygousnonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype.J Med Genet. 2003 Nov;40(11):845-8.
- Gerin I, Ury B, Breloy I, Bouchet-Seraphin C, Bolsée J, Halbout M, Graff J,Vertommen D, Muccioli GG, Seta N, Cuisset JM, Dabaj I, Quijano-Roy S, Grahn A,Van Schaftingen E, Bommer GT. ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto α-dystroglycan. Nat Commun. 2016 May 19;7:11534. doi: 10.1038/ncomms11534.
- Godfrey C, Escolar D, Brockington M, Clement EM, Mein R, Jimenez-Mallebrera C,Torelli S, Feng L, Brown SC, Sewry CA, Rutherford M, Shapira Y, Abbs S, MuntoniF. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy.Ann Neurol. 2006 Nov;60(5):603-10.
- Hayashi YK, Ogawa M, Tagawa K, Noguchi S, Ishihara T, Nonaka I, Arahata K.Selective deficiency of alpha-dystroglycan in Fukuyama-type congenital musculardystrophy. Neurology. 2001 Jul 10;57(1):115-21.
- Kanagawa M, Kobayashi K, Tajiri M, Manya H, Kuga A, Yamaguchi Y, Akasaka-ManyaK, Furukawa JI, Mizuno M, Kawakami H, Shinohara Y, Wada Y, Endo T, Toda T.Identification of a Post-translational Modification with Ribitol-Phosphate andIts Defect in Muscular Dystrophy. Cell Rep. 2016 Mar 8;14(9):2209-2223. doi:10.1016/j.celrep.2016.02.017.
- Kondo-Iida E, Kobayashi K, Watanabe M, Sasaki J, Kumagai T, Koide H, Saito K, Osawa M, Nakamura Y, Toda T. Novel mutations and genotype-phenotype relationshipsin 107 families with Fukuyama-type congenital muscular dystrophy (FCMD). Hum Mol Genet. 1999 Nov;8(12):2303-9.
- Murakami T, Hayashi YK, Noguchi S, Ogawa M, Nonaka I, Tanabe Y, Ogino M,Takada F, Eriguchi M, Kotooka N, Campbell KP, Osawa M, Nishino I. Fukutin genemutations cause dilated cardiomyopathy with minimal muscle weakness. Ann Neurol. 2006 Nov;60(5):597-602.
- Saito Y, Yamamoto T, Mizuguchi M, Kobayashi M, Saito K, Ohno K, Osawa M.Altered glycosylation of alpha-dystroglycan in neurons of Fukuyama congenitalmuscular dystrophy brains. Brain Res. 2006 Feb 23;1075(1):223-8.
- Toda T, Kobayashi K, Takeda S, Sasaki J, Kurahashi H, Kano H, Tachikawa M,Wang F, Nagai Y, Taniguchi K, Taniguchi M, Sunada Y, Terashima T, Endo T,Matsumura K. Fukuyama-type congenital muscular dystrophy (FCMD) andalpha-dystroglycanopathy. Congenit Anom (Kyoto). 2003 Jun;43(2):97-104. Review.
- Yis U, Uyanik G, Heck PB, Smitka M, Nobel H, Ebinger F, Dirik E, Feng L, KurulSH, Brocke K, Unalp A, Özer E, Cakmakci H, Sewry C, Cirak S, Muntoni F, Hehr U,Morris-Rosendahl DJ. Fukutin mutations in non-Japanese patients with congenitalmuscular dystrophy: less severe mutations predominate in patients with anon-Walker-Warburg phenotype. Neuromuscul Disord. 2011 Jan;21(1):20-30. doi:10.1016/j.nmd.2010.08.007.